Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Filament Health Corp. (FH) has completed two non-brokered private placements for gross proceeds of $2,500,080
  • The offerings included non-brokered private placements of 1,250 convertible debenture units and 9,616,000 units
  • Negev Capital was the sole investor in the convertible debenture unit financing
  • Filament Health is a clinical-stage natural psychedelic drug development company
  • Filament Health (FH) is unchanged on the day, trading at C$0.115 per share

Filament Health Corp. (FH) has completed two non-brokered private placements for gross proceeds of $2,500,080.

The offerings included a non-brokered private placement of 9,616,000 units priced at $0.13 per unit for gross proceeds of $1,250,080 and a non-brokered private placement of 1,250 convertible debenture units priced at $1,000 per debenture for gross proceeds of $1,250,000.

Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share for a period of 36 months.

Each convertible debenture unit includes a $1,000 unsecured convertible debenture and 6,667 warrants. Each warrant entitles the holder to purchase one additional common share for a period of 36 months. Each debenture is convertible into common shares at a price of $0.15.

Negev Capital was the sole investor in the convertible debenture unit financing. Filament Health has agreed to nominate a member of Negev Capital to its Board of Directors.

Filament Health is a clinical-stage natural psychedelic drug development company. 

Filament Health (FH) is unchanged on the day, trading at C$0.115 per share.

More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.

" Hemostemix (TSXV:HEM) announces $1.5M non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 5 million units for gross proceeds of up to $1.5 million.